​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie (ABBV) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $287.08, with a high of $315.00 and a low of $235.00. This represents a 14.38% increase from the last price of $250.98.

$150 $190 $230 $270 $310 $350 High: $315 Avg: $287.08 Low: $235 Last Closed Price: $250.98

ABBV Stock Rating

AbbVie stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (72.09%), 11 Hold (25.58%), 1 Sell (2.33%), and 0 Strong Sell (0.00%).

Buy
Total 43 1 11 31 Strong Sell Sell Hold Buy Strong Buy

ABBV Price Target Upside V Benchmarks

TypeNameUpside
StockAbbVie14.38%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks9.63%

Price Target Trends

1M3M12M
# Anlaysts41845
Avg Price Target$304.50$287.11$269.73
Last Closing Price$250.98$250.98$250.98
Upside/Downside21.32%14.40%7.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 268175-131
Aug, 268166-131
Jul, 268166-131
Jun, 268168--32
May, 268169--33
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Rajesh KumarHSBC$315.00$250.9825.51%25.51%
Aug 20, 2026Piper Sandler$303.00$265.9713.92%20.73%
Aug 17, 2026Wells Fargo$300.00$249.4520.26%19.53%
Aug 13, 2026Alexandria HammondWolfe Research$300.00$248.6620.65%19.53%
Aug 04, 2026Guggenheim$288.00$245.0817.51%14.75%
Aug 03, 2026Morgan Stanley$296.00$246.2620.20%17.94%
Aug 03, 2026Gary NachmanCanaccord Genuity$290.00$250.8815.59%15.55%
Jul 29, 2026Barclays$300.00$263.4813.86%19.53%
Jul 22, 2026Canaccord Genuity$282.00$256.1510.09%12.36%
Jul 13, 2026UBS$260.00$247.055.24%3.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026HSBCBuyBuyhold
Sep 08, 2026Bank of America SecuritiesBuyBuyhold
Aug 20, 2026Piper SandlerOverweightOverweighthold
Aug 17, 2026Wells FargoOverweightOverweighthold
Aug 13, 2026Wolfe ResearchPeer PerformOutperformupgrade
Aug 04, 2026GuggenheimBuyBuyhold
Aug 03, 2026Morgan StanleyOverweightOverweighthold
Jul 29, 2026BarclaysOverweightOverweighthold
Jul 15, 2026CitigroupNeutralNeutralhold
Jul 13, 2026UBSNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.48$6.65$2.73$2.40$2.38---
Avg Forecast$12.68$13.76$11.13$10.94$12.19$13.70$15.05$16.61
High Forecast$12.93$14.12$11.24$11.61$12.77$18.63$18.63$16.97
Low Forecast$12.43$13.34$11.08$10.67$11.57$7.28$7.23$15.93
Surprise %-48.90%-51.67%-75.47%-78.06%-80.48%---

Revenue Forecast

$50B $55B $60B $65B $70B $75B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$56.20B$58.05B$54.32B$56.33B$61.16B---
Avg Forecast$56.23B$58.27B$54.05B$56.04B$59.15B$63.51B$67.43B$71.61B
High Forecast$57.10B$59.43B$54.35B$56.19B$59.78B$63.52B$67.44B$72.82B
Low Forecast$55.40B$56.89B$53.94B$55.94B$58.25B$63.49B$67.41B$69.37B
Surprise %-0.07%-0.37%0.50%0.53%3.40%---

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.54B$11.84B$4.86B$4.28B$4.23B---
Avg Forecast$11.26B$13.10B$4.82B$19.75B$21.58B$14.78B$19.27B$29.44B
High Forecast$13.51B$15.72B$5.78B$20.59B$22.64B$33.03B$33.02B$30.08B
Low Forecast$9.01B$10.48B$3.86B$18.91B$20.51B$12.90B$12.83B$28.24B
Surprise %2.52%-9.67%0.89%-78.34%-80.41%---

ABBV Forecast FAQ

Is AbbVie stock a buy?

AbbVie stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that AbbVie is a favorable investment for most analysts.

What is AbbVie's price target?

AbbVie's price target, set by 43 Wall Street analysts, averages $287.08 over the next 12 months. The price target range spans from $235 at the low end to $315 at the high end, suggesting a potential 14.38% change from the previous closing price of $250.98.

How does AbbVie stock forecast compare to its benchmarks?

AbbVie's stock forecast shows a 14.38% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (9.63%).

What is the breakdown of analyst ratings for AbbVie over the past three months?

  • September 2026: 25.81% Strong Buy, 54.84% Buy, 16.13% Hold, 0% Sell, 3.23% Strong Sell.
  • August 2026: 25.81% Strong Buy, 51.61% Buy, 19.35% Hold, 0% Sell, 3.23% Strong Sell.
  • July 2026: 25.81% Strong Buy, 51.61% Buy, 19.35% Hold, 0% Sell, 3.23% Strong Sell.

What is AbbVie’s EPS forecast?

AbbVie's average annual EPS forecast for its fiscal year ending in December 2026 is $13.7, marking a 475.63% increase from the reported $2.38 in 2025. Estimates for the following years are $15.05 in 2027, and $16.61 in 2028.

What is AbbVie’s revenue forecast?

AbbVie's average annual revenue forecast for its fiscal year ending in December 2026 is $63.51B, reflecting a 3.84% increase from the reported $61.16B in 2025. The forecast for 2027 is $67.43B, and $71.61B for 2028.

What is AbbVie’s net income forecast?

AbbVie's net income forecast for the fiscal year ending in December 2026 stands at $14.78B, representing an 249.73% increase from the reported $4.23B in 2025. Projections indicate $19.27B in 2027, and $29.44B in 2028.